Labetalol | Hypertesion

The Rapeutic Effect of Milrinone Combined With Labetalol in Treatment of Severe Cardiopulmonary Failure Caused by Hand, Foot and Mouth Disesease

W. Li, et al. 

The aim of this study was to compare the effectiveness of two different protocols, labetalol with magnesium sulfate versus hydralazine with magnesium sulfate intravenous infusion with respect to their impact on maternal and fetal hemodynamics in severe preeclampsia. In conclusion; Milrinone combined with Labetalol significantly improves cardio-pulmonary function in cardio-pulmonary failure patient caused by severe hand, foot, mouth disease. Combined treatment significantly prevent disease progression and improves prognosis.

http://www.sciencepublishinggroup.com/j/ajp

A Study On Iv Labetalol Versus Oral Nifedipine In Acute Control Of Severe Hypertension In Pregnancy

G. Kesava Chandra, et al.

The aim of this study is to compare the efficacy of IV Labetalol with oral Nifedipine in the treatment of severe hypertension in pregnancy with blood pressure >160/110mm Hg. In conclusion; IV Labetalol and oral Nifedipine were equally effectively to achieve target blood pressure. Incomparsion, oral Nifedipine achieved target blood pressure more quickly than Labetalol.

https://pubmed.ncbi.nlm.nih.gov/30878897/

Impact of intravenous infusion of labetalol combined with magnesium sulfate versus hydralazine combined with magnesium sulfate on fetomaternal hemodynamics in severe preeclampsia

T.N. Abdelrahman, et al.

The aim of this study was to compare the effectiveness of two different protocols, labetalol with magnesium sulfate versus hydralazine with magnesium sulfate intravenous infusion with respect to their impact on maternal and fetal hemodynamics in severe preeclampsia. We concluded that both labetalol and hydralazine intravenous infusion regimens are well tolerated and effective in controlling severe hypertension in pregnant women with severe preeclampsia in combination with magnesium sulfate. Both drugs are reassuring as they are not related to any significant changes in fetoplacental

circulation. Fetal heart rate did not change significantly after treatment in both groups.

https://link.springer.com/article/10.1186/s42077-019-0020-3

Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients

M.F. Gaynor, et al.

The aim of this study was to evaluate the use of as-needed (PRN) labetalol and hydralazine [intravenous (IV) or oral] in hospitalized medicine patients for the treatment of severe asymptomatic hypertension and to examine the potential negative outcomes associated with their use. In conclusion; As-needed oral hydralazine is frequently prescribed for acute blood pressure lowering with administration thresholds often less than what are used to define acute severe hypertension. Many patients are prescribed PRN antihypertensive medication instead of being continued on their home regimens, and most patients do not have the intensity of their home regimens increased. Providers need to be educated about the use of PRN antihypertensive medication for the management of severe asymptomatic hypertension in the hospital setting.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933643/

Comparison of Hydralazine and Labetalol to lower severe hypertension in pregnancy

Khan, et al.

The aim of this study is to compare the intravenous Labetalol versus intravenous hydralazine in patients having severe Pregnancy induced hypertension (PIH) and pre-eclampsia (PE) in pregnancy. In conclusion; Intra Venous labetalol lowered MAP more than hydralazine, when administered to pregnant females with severe Pregnancy induced hypertension and pre eclampsia in pregnancy.

https://doi.org/10.12669/pjms.332.12243